Immuron Ltd (IMRN)
About Immuron Ltd
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $10.2M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $10.2M
- Shares outstanding
- 9.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 13, 2007
Immuron Ltd (IMRN) Stock Price
- Trading 53% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Immuron Ltd.
Write a review
News about Immuron Ltd
News & sentiment via Polygon.io
Immuron Ltd: frequently asked questions
Is Immuron Ltd an American company?
Immuron Ltd is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Immuron Ltd publicly traded?
Yes — Immuron Ltd is a publicly traded company. Its stock trades under the ticker symbol IMRN on the NASDAQ.
What does Immuron Ltd do?
Immuron Ltd is an American Pharmaceuticals company in the Health & Beauty sector.
